124,449 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Haven Capital Group Inc.

Haven Capital Group Inc. bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 124,449 shares of the biotechnology company’s stock, valued at approximately $921,000. Iovance Biotherapeutics accounts for 0.9% of Haven Capital Group Inc.’s portfolio, making the stock its 22nd biggest position.

Other institutional investors also recently bought and sold shares of the company. Assetmark Inc. grew its stake in shares of Iovance Biotherapeutics by 48.0% in the third quarter. Assetmark Inc. now owns 12,853 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 4,167 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Iovance Biotherapeutics during the 3rd quarter worth $242,000. Victory Capital Management Inc. increased its holdings in Iovance Biotherapeutics by 399.4% during the 3rd quarter. Victory Capital Management Inc. now owns 144,280 shares of the biotechnology company’s stock worth $1,355,000 after purchasing an additional 115,387 shares during the period. Grandfield & Dodd LLC acquired a new stake in Iovance Biotherapeutics in the 3rd quarter valued at about $282,000. Finally, Intech Investment Management LLC purchased a new position in shares of Iovance Biotherapeutics in the 3rd quarter valued at about $920,000. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Stock Performance

Iovance Biotherapeutics stock opened at $3.74 on Tuesday. The company has a market capitalization of $1.23 billion, a P/E ratio of -2.51 and a beta of 0.93. Iovance Biotherapeutics, Inc. has a fifty-two week low of $3.48 and a fifty-two week high of $15.90. The stock has a 50-day simple moving average of $5.40 and a 200-day simple moving average of $7.96.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.26). The company had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. As a group, analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IOVA. Chardan Capital cut their target price on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Robert W. Baird lowered their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, February 28th. Truist Financial cut their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group lowered their price objective on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.